Lilly Raises Sales Outlook as Weight-Loss Demand Powers Growth

Eli Lilly raised its annual sales forecast after strong demand for Mounjaro and Zepbound. Pricing pressure, acquisition charges and temporary revenue benefits add complexity to the earnings picture.

Eli Lilly’s latest results show the strength of demand for its diabetes and weight-loss treatments—and the growing importance of pricing.

The drugmaker (NYSE: LLY) reported third-quarter revenue of $24.4 billion, up 39%. Sales volumes increased 53%, more than offsetting a 15% decline in realised prices.

Lilly raised its full-year revenue forecast to $91 billion–$92 billion, increasing the midpoint by $5.5 billion. Adjusted quarterly earnings reached $7.48 per share.

The profit outlook requires a closer look. Lilly now expects annual adjusted earnings of $35–$36 per share. Improved underlying performance was more than offset by acquired research and development charges from recent deals.

The quarter also included approximately $900 million in revenue benefits, including milestone payments and adjustments to rebate and discount estimates. Those benefits should be considered when assessing the pace of recurring growth.

Mounjaro generated $10.72 billion in sales, while Zepbound contributed $5.35 billion. Both exceeded Wall Street expectations. However, Lilly’s newer obesity pill, Foundayo, delivered $184 million, below forecasts.

For shareholders, the opportunity remains substantial. Expanding access can bring more patients into treatment, but lower prices mean prescription growth must keep translating into profitable sales.

Investor Take: Lilly’s higher sales forecast supports its growth story. The key measures ahead are sustained demand, pricing and margins. Investors should also distinguish operating progress from acquisition charges and revenue benefits when judging the underlying business.